Moderate

Thyroiditis (subacute de Quervain, postpartum, silent/painless, drug-induced)

thyroid · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Destructive/inflammatory release of preformed hormone causing transient thyrotoxicosis, often followed by hypothyroid phase then recovery. Subacute (de Quervain): painful tender goitre, post-viral, raised ESR/CRP. Postpartum and silent: painless, autoimmune (anti-TPO+). Drug-induced: amiodarone type 2, lithium, interferon, checkpoint inhibitors. Key feature: LOW radioiodine uptake (distinguishes from Graves).

Red flags

  • Septic, exquisitely tender, fluctuant thyroid = suppurative thyroiditis — antibiotics, imaging, drainage
  • Rapidly enlarging hard mass, stridor, hoarseness — exclude malignancy/Riedel/haemorrhage
  • Severe thyrotoxicosis with storm features
  • Amiodarone thyrotoxicosis with cardiac decompensation

Assessment

Differential diagnosis

  • Graves disease / toxic nodular goitre (HIGH uptake — needs antithyroid drug)
  • Acute suppurative (bacterial) thyroiditis (very tender, septic, abscess — needs antibiotics/drainage)
  • Thyroid haemorrhage into cyst / rapidly enlarging nodule
  • Pharyngitis / anterior neck infection (pain referral)
  • Amiodarone-induced thyrotoxicosis type 1 vs type 2

Investigations

  • TSH, free T4, free T3 (thyrotoxic early, hypothyroid later)
  • ESR/CRP (markedly raised in subacute de Quervain)
  • Anti-TPO antibodies (positive in postpartum/silent/Hashimoto)
  • Radioiodine/technetium uptake — LOW/absent uptake confirms destructive thyroiditis (avoid in pregnancy/lactation)
  • Thyroid ultrasound with Doppler (low vascularity vs Graves hypervascularity; helps amiodarone type)
  • TRAb if Graves cannot be excluded clinically

Management

  • Confirm destructive pattern (low uptake, or clinical + ESR) — do NOT start carbimazole (no new hormone synthesis)
  • Thyrotoxic phase: symptom control with beta-blocker; pain control
  • Subacute de Quervain: NSAID first-line; prednisolone if severe pain or NSAID failure, taper over weeks
  • Monitor through phases: thyrotoxic (weeks) then often hypothyroid (weeks-months) then recovery
  • Hypothyroid phase: levothyroxine only if symptomatic or prolonged; many recover spontaneously
  • Postpartum thyroiditis: recheck TSH — up to a quarter become permanently hypothyroid; annual TSH thereafter
  • Amiodarone type 2: glucocorticoids; type 1: antithyroid drug; mixed/unclear — treat both, discuss stopping amiodarone with cardiology

Drugs & doses

Propranolol 20-40 mg PO 6-8 hourly for thyrotoxic symptoms
Ibuprofen 400 mg PO tds or naproxen 500 mg PO bd for subacute thyroiditis pain
Prednisolone 30-40 mg PO od for severe subacute thyroiditis, taper over 4-6 weeks
Levothyroxine 50-100 µg PO od ONLY if symptomatic/prolonged hypothyroid phase (often temporary)
Prednisolone 30-40 mg PO od for amiodarone-induced thyrotoxicosis type 2 [verify local]

Disposition

Outpatient with interval TSH monitoring (e.g. 6-8 weekly through phases). Admit only for suppurative thyroiditis, airway concern, or severe thyrotoxicosis.

Complications & pitfalls

  • Permanent hypothyroidism (notably postpartum and drug-induced)
  • Recurrent postpartum thyroiditis in subsequent pregnancies
  • Transient atrial fibrillation in thyrotoxic phase
  • Prolonged symptomatic hypothyroid phase

Exam pearls

  • The single most useful discriminator from Graves is radioiodine uptake: LOW in thyroiditis, HIGH in Graves — antithyroid drugs do nothing for destructive thyroiditis.
  • de Quervain classically follows an URTI with a painful goitre and very high ESR; responds dramatically to steroids.
  • Checkpoint-inhibitor (immunotherapy) thyroiditis is increasingly common — a brief thyrotoxic phase then hypothyroidism needing levothyroxine.
  • Always recheck TSH after postpartum thyroiditis — a significant minority stay hypothyroid.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.